BRS2-1-2 - Betaine/BHMT Remethylation
(Regenerating methionine from homocysteine with betaine)
1. Mission & Overview + Dietary Levers
Mission
Provide a parallel homocysteine clearance route so methionine and SAMe supply remain resilient when folate demand is high.
Intervention Dominance: Diet-Dominant
- Betaine - (dietary methyl donor)
- Choline - (methylation support nutrient)
- Zinc
- Homocysteine - (remethylation substrate)
KC1’s betaine/choline relationship is conditionally admitted under demonstrated depletion. Its full provision disclosures and attached depletion limits remain under the Direct/Derived requirements; identical KC disclosures are consolidated there. Folate’s proposed indirect constraint remains unresolved and audit-only.
Overview
Betaine–homocysteine methyltransferase transfers a methyl group from betaine to homocysteine, forming methionine and dimethylglycine. [1] A bound zinc ion activates homocysteine. [1] [2] Folate and vitamin B12 are not part of that reaction. [3] Betaine may come from the diet or from oxidation of choline. [3] [4] In healthy men, controlled choline depletion lowered plasma betaine and reduced homocysteine-handling reserve, and repletion reversed that change. [6]
- Benefits: This route replenishes methionine, and with it the capacity to handle a homocysteine load, without using folate or vitamin B12. [1] [3] In the men who became clinically depleted, that reserve fell with the betaine pool and returned after repletion. [6]
- Implementation Notes: Betaine and choline are the provision routes. [3] [6] The bound zinc ion is part of the enzyme, not a dietary zinc target. [1] [2] Choline depletion lowered the betaine pool; that study does not set a dose for people whose supply is already adequate. [6]
- Biological Relevance: Folate- and vitamin B12-dependent remethylation is a neighbouring reaction, not this methyl transfer. [3]
2. Primary Biological Effects
↑ folate-independent remethylation of homocysteine to methionine
↑ methionine available for later SAMe formation
→ no direct claim that this reaction itself raises SAMe or improves symptoms
3. Intervention Levers
No preparation, supplementation schedule, fasting pattern, light exposure or stress practice has been shown to change this reaction beyond the betaine and choline relationships above.
No sleep, stress-recovery, activity or meal-timing effect on this reaction has been established.
4. Mechanistic Basis + Scientific Findings (SFs 3)
Summary
Homocysteine (an amino acid left after methyl groups are used) can be turned back into methionine by a betaine-dependent reaction that does not use folate or vitamin B12. The methionine can later be used to make SAMe, but this reaction stops at methionine. A fall in plasma homocysteine after betaine is taken is a blood result, not a measurement of how fast the enzyme is working in tissue.
SF1 — BHMT remethylates homocysteine with betaine and catalytic zinc
BHMT moves one methyl group from betaine (trimethylglycine) onto homocysteine. The products are methionine and dimethylglycine (what remains of betaine after that methyl group leaves) [Breksa and Garrow (1999) [2]; Evans et al. (2002) [1]]. A zinc ion held by three cysteines in the active site activates the homocysteine thiol. Changing any of those cysteines to alanine abolishes activity in the recombinant human enzyme [2]. Human structures capture both a zinc-free oxidised form and a zinc-bound form [1].
Supporting evidence: SF1 — BHMT remethylates homocysteine with betaine and catalytic zinc.
(What the reaction does not use)
Folate and vitamin B12 are required by the parallel methionine-synthase route. They are not substrates or cofactors of this transfer. Methyl flow through BHMT does not depend on them [Obeid (2013) [3]]. The enzyme is especially active in liver and kidney rather than throughout the brain [2], [3].
SF2 — Choline oxidation supplies betaine and is not the BHMT reaction
Choline can be oxidised to betaine aldehyde by choline dehydrogenase, then to betaine by betaine-aldehyde dehydrogenase. That oxidation is irreversible, so it can feed betaine into BHMT without being the BHMT reaction itself [Obeid (2013) [3]; Salvi and Gadda (2013) [4]]. Human choline dehydrogenase sits in the inner mitochondrial membrane and is found mainly in kidney and liver [4].
Supporting evidence: SF2 — Choline oxidation supplies betaine and is not the BHMT reaction.
SF5 — Betaine availability and choline supply can constrain remethylation reserve
Inadequate betaine availability, including from conditional failure of choline provision, can constrain BHMT-dependent homocysteine remethylation capacity. Evans et al. (2002) [1]; da Costa et al. (2005) [6]; Setoue et al. (2008) [12]; Strakova et al. (2011) [13]
Supporting evidence: SF5 — Betaine availability and choline supply can constrain remethylation reserve.
(Plasma homocysteine is a shared marker)
In healthy adults, 1.5–6 g/day of supplemental betaine lowered fasting plasma homocysteine over six weeks [Olthof et al. (2003) [5]]. Experimental choline depletion raised homocysteine after a methionine load in mice and in a pilot of eight men, without a fall in mouse liver betaine and without an enzyme assay [da Costa et al. (2005) [6]]. Vitamin B12 and fish oil also lower plasma homocysteine, so the same blood result is not specific to this enzyme [Huang et al. (2015) [7]].
(Boundaries of the mechanism)
This PM is the betaine-dependent methyl transfer only.
Folate/B12-dependent remethylation belongs to BRS2-FM1-PM1. Methionine-to-SAMe conversion belongs to BRS2-FM1-PM3. Combined cycle throughput belongs to BRS2-FM1-PM4.
SAMe-dependent phosphatidylethanolamine methylation belongs to BRS2-FM3-PM7. Acetylcholine formation from choline belongs to BRS1-FM2-PM6.
(Integration within BRS2)
Within BRS2(FM1) — Methylation Cycle Efficiency, this reaction is one way to regenerate methionine when the folate-dependent route is under strain [Obeid (2013) [3]]. The methionine can enter SAMe formation afterwards. Whether a shortfall in the wider methyl-donor pool limits the enzyme's activity in people has not been shown, because plasma homocysteine does not measure that activity [5], [6].
4.1 Scientific Findings (3)
Summary
Human structure and mutagenesis studies establish BHMT’s betaine-dependent reaction and catalytic zinc requirement. [1] [2] Controlled human choline depletion lowered plasma betaine and worsened the homocysteine response to a methionine challenge in participants who developed hepatic steatosis; repletion restored that response. [6] Animal depletion and enzyme-inhibition studies complement this supported dependency chain, but human tissue BHMT flux and cognitive outcomes were not measured. [12] [13]
Human betaine-homocysteine methyltransferase (BHMT) transfers one methyl group from betaine to homocysteine. The products are methionine and dimethylglycine. A zinc ion bound by three cysteines activates homocysteine. Folate and vitamin B12 are not part of this reaction.
What this means
This is the reaction boundary. It does not include folate-dependent remethylation, the later conversion of methionine to SAMe, whole-cycle throughput, phosphatidylethanolamine methyltransferase, or acetylcholine formation. It also does not show that dietary zinc intake changes the reaction in people.
Evidence confidence: Not yet scored
Finding ID: PM2-F1
Finding Statement: BHMT transfers a methyl group from betaine to homocysteine, forming methionine and dimethylglycine, without folate or vitamin B12 in that reaction, and uses an active-site zinc ion to activate homocysteine.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Human crystal structures show that BHMT makes methionine from betaine and homocysteine and uses zinc to activate homocysteine. Mutating any of the three zinc-binding cysteines to alanine abolishes activity and sharply reduces zinc binding, and the same biochemical work states the products as methionine and dimethylglycine. A methyl-donor review states that methyl flow through this pathway does not depend on folate or vitamin B12. Together these sources identify the reaction and its metal. They do not test ordinary dietary control or human tissue flux.
Synthesis Limitations: The enzyme evidence uses purified or recombinant human protein, not intact human metabolism. Loss of activity after removing zinc ligands does not show that dietary zinc usually limits the enzyme. The review statement that the pathway is independent of folate and vitamin B12 is not a new flux experiment. Quantitative claims in that review about choline deficiency and liver methionine were not re-checked in the primary animal papers.
Evidence Considered:
- Study
- X-ray structures of human BHMT in an oxidised zinc-free form and a reduced zinc-bound form with a homocysteine-like bisubstrate analog.
- Population
- Purified crystallised human BHMT; no cells, animals or human participants.
- Result
- The enzyme forms methionine from betaine and homocysteine. Zinc activates homocysteine. The zinc-binding sequences sit at the ends of barrel strands, and a Cys217–Cys299 disulfide expels zinc.
- Effect / Magnitude
- Structures at 2.15 Å (zinc-free) and 2.05 Å (zinc-bound). No physiological effect size applies.
- Evidence Summary
- Direct structural evidence for the human reaction and for catalytic zinc.
- Limitations
- Static structures establish catalytic geometry, not in-vivo flux, dietary zinc responsiveness, or a clinical outcome.
- Evidence Source
- Bounded external search
- Reference
- [1]
- Study
- Site-directed mutagenesis of recombinant human liver BHMT, with activity and zinc-binding measurements.
- Population
- Recombinant human BHMT protein expressed in bacteria; no human participants.
- Result
- Cys217, Cys299 and Cys300 were identified as zinc ligands. Mutation of any one to alanine caused complete loss of activity and a significant reduction in zinc binding. The catalysed transfer is from betaine to homocysteine, yielding dimethylglycine and methionine.
- Effect / Magnitude
- Complete loss of activity for each alanine substitution. No human effect size applies.
- Evidence Summary
- Direct evidence that catalytic activity of human BHMT depends on those zinc ligands, and a clear statement of the reaction products.
- Limitations
- Bacterial expression and purified-protein assays do not show that dietary zinc limits BHMT in human tissues.
- Evidence Source
- Bounded external search
- Reference
- [2]
- Study
- Narrative review of methyl-donor deficiency with emphasis on the BHMT pathway.
- Population
- Review of human and animal methyl-donor studies; not a new experiment.
- Result
- BHMT transfers a methyl group from betaine to homocysteine. The review states that methyl flow through this pathway is not dependent on folate or vitamin B12, while several cross-talk mechanisms exist. BHMT is particularly active in liver and kidney.
- Effect / Magnitude
- No new effect size. The review cites other studies for homocysteine and metabolite changes.
- Evidence Summary
- Explicit pathway-level statement that folate and vitamin B12 are not required for methyl flow through BHMT.
- Limitations
- A review cannot replace a flux assay. Some quantitative deficiency claims are attributed to other papers and were not re-adjudicated here.
- Evidence Source
- Bounded external search
- Reference
- [3]
Evidence Dependency:
- Obeid (2013) is also primary evidence in PM2-F2 for choline oxidation. That reuse is one review, not a second experiment.
Informs: Focus / Attention Stability
Mechanistic explanation: BHMT remethylates homocysteine with betaine and catalytic zinc
Choline can be oxidised to betaine aldehyde and then to betaine. That sequence can supply the BHMT substrate. It is not the methyl transfer that BHMT carries out, and betaine is not turned back into choline.
What this means
Choline is a precursor of the substrate, not a cofactor or substrate of BHMT. Acetylcholine formation and phosphatidylethanolamine methylation use choline or SAMe in other reactions.
Evidence confidence: Not yet scored
Finding ID: PM2-F2
Finding Statement: Irreversible oxidation of choline to betaine is an upstream supply route for the BHMT substrate and is not itself the BHMT reaction.
Synthesised Evidence Confidence: Not yet scored
Synthesis: A methyl-donor review states that betaine is produced by irreversible oxidation of choline through choline dehydrogenase and betaine-aldehyde dehydrogenase, and that BHMT then uses betaine. A choline-dehydrogenase review places the human enzyme in the inner mitochondrial membrane, mainly in kidney and liver, and separates the first oxidation to betaine aldehyde from the second oxidation to betaine. Betaine then donates a methyl group in the homocysteine-to-methionine reaction. The two steps are supply, not the BHMT reaction.
Synthesis Limitations: Purified, stable human choline dehydrogenase has been difficult to obtain, so some catalytic detail is inferred from related enzymes and from tissue activity rather than from a complete human kinetic characterisation. The reviews do not show that raising choline intake increases BHMT flux in people.
Evidence Considered:
- Study
- Narrative review of methyl-donor metabolism centred on BHMT.
- Population
- Review of human and animal evidence; not a new enzyme assay.
- Result
- The review states the two-enzyme oxidation of choline to betaine and the subsequent BHMT reaction. It treats the oxidation as irreversible.
- Effect / Magnitude
- No new effect size for the oxidation steps.
- Evidence Summary
- Pathway-level evidence that choline oxidation supplies betaine upstream of BHMT.
- Limitations
- Review synthesis, not a direct demonstration of human choline dehydrogenase kinetics or of dietary choline increasing BHMT flux.
- Evidence Source
- Bounded external search
- Reference
- [3]
- Study
- Review of human choline dehydrogenase localisation, physiological role and biochemical characterisation.
- Population
- Review of human tissue activity and comparative biochemistry; not a dietary trial.
- Result
- The enzyme sits in the inner mitochondrial membrane and is found mainly in kidney and liver. It oxidises choline to betaine aldehyde. A second enzyme, betaine-aldehyde dehydrogenase, oxidises that aldehyde to betaine. Betaine is described as a methyl donor for methionine formation from homocysteine. Purified active human enzyme has been difficult to obtain.
- Effect / Magnitude
- Tissue activity was reported mainly in kidney, with about six-fold lower activity in liver. No dietary dose-response was measured.
- Evidence Summary
- Enzyme-level support for the two-step oxidation that supplies betaine.
- Limitations
- Incomplete purification of human choline dehydrogenase limits kinetic detail. Localisation and pathway role do not show that dietary choline changes BHMT flux.
- Evidence Source
- Bounded external search
- Reference
- [4]
Evidence Dependency:
- Obeid (2013) is also primary evidence in PM2-F1 for folate- and vitamin B12-independence of BHMT. That reuse is one review, not a second experiment.
Mechanistic explanation: Choline oxidation supplies betaine and is not the BHMT reaction
Controlled human choline depletion lowered plasma betaine and reduced challenged remethylation reserve in participants who developed clinical depletion. In rats, choline deprivation lowered hepatic betaine and the phenotype was suppressed by choline or betaine; specific BHMT inhibition independently produced the expected pathway failure.
What this means
Together with the established BHMT reaction, these intervention, pool, rescue and specific-inhibition edges support a constraint on betaine-dependent remethylation capacity. They do not directly measure human tissue BHMT flux or show a benefit from intake above adequacy.
Evidence confidence: Not yet scored
Finding ID: PM2-F5
Finding Statement: Inadequate betaine availability, including from conditional failure of choline provision, can constrain BHMT-dependent homocysteine remethylation capacity.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Da Costa et al. fed eight healthy men a 550 mg/day choline baseline diet followed by 50 mg/day for up to 42 days. Plasma choline and betaine fell by about 30% and 47% while folate remained adequate. In the four participants who developed hepatic steatosis, post-load homocysteine was 5.2 µmol/L higher and returned to the baseline response after repletion. In rats under low-methionine conditions, Setoue et al. found that choline deprivation markedly lowered hepatic betaine and raised plasma homocysteine, while either choline or betaine restored hepatic betaine and suppressed the increase. Strakova et al. independently showed that a specific BHMT inhibitor reduced liver BHMT activity by more than 90%, raised plasma homocysteine two- to five-fold and lowered liver SAM by more than 40%. Human BHMT biochemistry establishes betaine as the methyl donor. These edges form a supported constraint chain.
Synthesis Limitations: The human study was a pilot in eight men, with the challenged response confined to four clinically depleted participants. The pool-rescue and specific-inhibition evidence is from rat liver, and neither study measured isotope-resolved human BHMT flux. Choline partitioning, endogenous synthesis and methionine/folate state modify the provision route. The chain supports capacity constraint under demonstrated depletion, not universal limitation on ordinary diets, benefit from supplementation above adequacy, or a cognitive outcome.
Evidence Considered:
- Study
- Controlled depletion–repletion pilot with a methionine-load challenge.
- Population
- Eight healthy men aged 20–46 years; four developed hepatic steatosis during depletion.
- Result
- Plasma choline and betaine fell about 30% and 47% in the full group. In the four clinically depleted men, post-load homocysteine increased by 5.2 µmol/L (95% CI 1.2–9.1; P = 0.025) relative to the 550 mg/day baseline phase and returned to the baseline response after repletion. Folate did not fall.
- Effect / Magnitude
- Betaine fell from 66 ± 7 to 35 ± 2 nmol/mL in all eight men; clinically depleted participants had a 5.2 µmol/L greater post-load homocysteine response.
- Evidence Summary
- Human intervention evidence linking choline inadequacy, lower betaine availability and reduced remethylation reserve under challenge.
- Limitations
- Small male-only pilot, severe controlled depletion, shared circulating endpoint, and no direct tissue or isotope-resolved BHMT flux.
- Evidence Source
- Bounded external search
- Reference
- [6]
- Study
- X-ray structural analysis of human BHMT.
- Population
- Purified human BHMT; no participants.
- Result
- BHMT transfers a methyl group from betaine to homocysteine to form methionine and dimethylglycine.
- Effect / Magnitude
- No human intervention effect size.
- Evidence Summary
- Provides reaction-specific attribution for the donor-pool intervention chain.
- Limitations
- Purified-enzyme evidence does not itself establish dietary constraint.
- Evidence Source
- Bounded external search
- Reference
- [1]
- Study
- Controlled rat feeding experiments varying choline, methionine context and lipotrope rescue.
- Population
- Male Wistar rats fed casein- or soybean-protein-based diets.
- Result
- On the choline-deprived soybean-protein diet, hepatic betaine fell from about 3.65 to 0.13 µmol/g and plasma homocysteine rose from about 12.5 to 33.5 µmol/L. Choline or betaine supplementation restored hepatic betaine to about 9.81 or 13.3 µmol/g and lowered plasma homocysteine to about 7.3 or 7.7 µmol/L. Ex-vivo BHMT activity did not decline.
- Effect / Magnitude
- Approximately 96% lower hepatic betaine with deprivation; rescue restored the pool above control and suppressed hyperhomocysteinaemia.
- Evidence Summary
- Pool depletion and rescue connect conditional choline inadequacy to loss of substrate-supported remethylation capacity rather than loss of BHMT protein competence.
- Limitations
- Rat liver model under low-methionine conditions; homocysteine removal also involved transsulfuration, and no in-vivo isotope-resolved BHMT flux was measured.
- Evidence Source
- Bounded external search
- Reference
- [12]
- Study
- Rat feeding study using the potent and specific BHMT inhibitor S-(δ-carboxybutyl)-L-homocysteine for 3 or 14 days across adequate, cysteine-free and methionine-deficient diets.
- Population
- Rats; no human participants.
- Result
- The inhibitor reduced liver BHMT activity by more than 90%, increased plasma homocysteine two- to five-fold and lowered hepatic SAM by more than 40% across dietary conditions.
- Effect / Magnitude
- >90% lower BHMT activity; 2–5-fold higher plasma homocysteine; >40% lower liver SAM.
- Evidence Summary
- Specific perturbation confirms that impaired BHMT capacity can generate the observed remethylation and methylation-state direction.
- Limitations
- Pharmacological inhibition in rats does not quantify the effect of ordinary human betaine or choline intake.
- Evidence Source
- Bounded external search
- Reference
- [13]
Evidence Dependency:
- Da Costa et al. (2005) is also used in PM2-IC1. PM2-IC1 establishes that plasma homocysteine alone is non-specific; PM2-F5 relies on the combined depletion, pool, challenge, repletion and reaction chain rather than treating that biomarker alone as BHMT flux.
- Evans et al. (2002) is also primary evidence in PM2-F1. Its reuse in PM2-F5 supplies the same reaction-specific link and is not independent replication.
Mechanistic explanation: Betaine availability and choline supply can constrain remethylation reserve
5. BRS Pathways and Connections
5.1 BRS Pathways
BRS2-FM1-PM2 — Betaine/BHMT Remethylation
↓
BRS2-FM1-PM3 — SAMe Synthesis
5.2 Cross-BRS Mechanism Relationships
Primary Mechanisms in other Biological Regulatory Systems that directly interact with, constrain or support this mechanism.
- BRS1-FM2-PM6 — Acetylcholine Synthesis Support — Choline that is oxidised becomes betaine for this methyl transfer, while choline that is not oxidised is the substrate used to make acetylcholine. Betaine is not converted back to choline, so this shared use of choline does not show that dietary betaine raises brain acetylcholine.
5.3 Local BRS Mechanism Relationships
Related Primary Mechanisms within the same Biological Regulatory System that collectively support the integrated biological function.
- BRS2-FM1-PM1 — Folate/B12-Dependent Homocysteine Remethylation — This sibling regenerates methionine from homocysteine by methionine synthase, using a folate-derived methyl group and vitamin B12. BHMT uses betaine instead, so the routes are parallel and folate is not a cofactor of this reaction.
- BRS2-FM1-PM3 — SAMe Synthesis — Methionine produced here can be joined to ATP by methionine adenosyltransferase to form the later methyl donor. That conversion is a separate enzyme step and is not catalysed by BHMT.
- BRS2-FM1-PM4 — Methionine Cycle Flux — The wider methionine cycle combines remethylation, methyl-group use and regeneration into one throughput. This PM is only the betaine-dependent remethylation step, not that combined throughput.
7. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework.
Each Phenome relationship has two independent ratings. They are not combined or averaged.
Biology → Phenome Relationship Strength
How direct and important is this biological mechanism expected to be to the Phenome within the BRAIN model?
Evidence Confidence
How strongly does the adjudicated evidence support this particular biology → Phenome relationship?
- Biology → Phenome Relationship Strength: Low–Medium
- Evidence Confidence: Low–Medium
- Rationale: Reviews of ADHD diets and of choline in neurodevelopment discuss attention, but they do not test BHMT activity or betaine supplementation as an attention treatment Derbyshire and Maes (2023) [8]; Millichap and Yee (2012) [9]. The enzyme reaction is established separately, and a change in plasma homocysteine is not an attention outcome Evans et al. (2002) [1]; Olthof et al. (2003) [5]. Direct evidence that this remethylation route changes Focus / Attention Stability remains a gap.
Supporting evidence
The attached attention reviews discuss dietary patterns, supplements and choline in neurodevelopment. They do not measure BHMT or test betaine as a treatment for attention.
What this means
An attention relationship can remain a framework bridge. It should not be read as evidence that this remethylation route changes focus.
Evidence confidence: Not yet scored
Finding ID: PM2-F3
Finding Statement: The repository ADHD diet review and choline neurodevelopment review do not directly demonstrate that BHMT-dependent remethylation changes Focus / Attention Stability.
Synthesised Evidence Confidence: Not yet scored
Synthesis: One review surveys sugar restriction, additive-free diets, elimination diets, fatty acids, iron and zinc in ADHD. Another surveys choline status in autism, ADHD and dyslexia. Neither assigns an attention outcome to BHMT activity or to betaine supplementation. The biochemical reaction can be true while this phenome link stays untested.
Synthesis Limitations: This is a gap in the attached reviews, not proof that no attention relationship exists. The sources are narrative reviews and mix many dietary exposures.
Evidence Considered:
- Study
- Narrative clinical review of diet as a treatment factor in ADHD.
- Population
- Children with ADHD in the reviewed literature; not a BHMT cohort.
- Result
- Discusses restriction diets, fatty-acid supplements, iron, zinc and dietary pattern. No betaine dose, BHMT assay or homocysteine remethylation endpoint is the basis of the conclusions.
- Effect / Magnitude
- No BHMT or betaine effect size is reported.
- Evidence Summary
- Shows why an ADHD diet review cannot be used as direct evidence for this reaction.
- Limitations
- Narrative review spanning many exposures and outcomes. Not a mechanism test.
- Evidence Source
- Inherited repository evidence
- Reference
- [9]
- Study
- Narrative review of choline and neurodevelopmental disorders.
- Population
- Pregnancy, children with autism, and people with ADHD or dyslexia in the reviewed literature.
- Result
- Low choline intake or altered choline status is discussed for those groups. The review does not test BHMT, betaine supplementation or tissue remethylation flux against attention scores.
- Effect / Magnitude
- No BHMT effect size is reported.
- Evidence Summary
- Choline neurodevelopment context is not a BHMT outcome study.
- Limitations
- Narrative review. Choline has membrane and neurotransmitter roles outside this reaction.
- Evidence Source
- Inherited repository evidence
- Reference
- [8]
Evidence Dependency:
- Derbyshire and Maes (2023) is also primary evidence in PM2-F4. That reuse is one review, not independent replication.
Informs: Focus / Attention Stability
- Biology → Phenome Relationship Strength: Low
- Evidence Confidence: Low
- Rationale: Lower plasma homocysteine after betaine supplements is a blood measurement, not a test of cognitive clarity or of tissue BHMT activity Olthof et al. (2003) [5]. A choline review discusses neurodevelopment rather than an effect of this reaction on clarity Derbyshire and Maes (2023) [8]. The relationship remains an indirect bridge with no direct outcome evidence.
Supporting evidence
Betaine can lower plasma homocysteine, and choline is discussed in neurodevelopment. Neither result shows that BHMT activity changes cognitive clarity.
What this means
Cognitive clarity stays an indirect bridge. Do not treat a homocysteine change, or a choline review, as a clarity outcome for this PM.
Evidence confidence: Not yet scored
Finding ID: PM2-F4
Finding Statement: Plasma homocysteine lowering after betaine, and narrative choline reviews, do not directly demonstrate that BHMT-dependent remethylation changes Cognitive Clarity.
Synthesised Evidence Confidence: Not yet scored
Synthesis: The betaine trial measured plasma homocysteine in healthy adults and did not measure cognition. The choline review discusses neurodevelopmental conditions rather than clarity as an outcome of this reaction. Both can sit near methyl-donor biology without testing the phenome claim.
Synthesis Limitations: Bounded to the attached sources. Absence of a clarity endpoint in these papers is not a universal negative finding.
Evidence Considered:
- Study
- Six-week randomised betaine supplementation trial with methionine loads.
- Population
- Healthy adults in four groups of 19.
- Result
- Fasting and post-load plasma homocysteine fell relative to placebo. No cognitive clarity scale was used.
- Effect / Magnitude
- Fasting homocysteine about 12%, 15% and 20% lower than placebo at 1.5, 3 and 6 g/day. No cognitive effect size exists in the study.
- Evidence Summary
- Human homocysteine evidence without a clarity endpoint.
- Limitations
- Healthy adults, circulating endpoint, no cognitive measurement.
- Evidence Source
- Inherited repository evidence
- Reference
- [5]
- Study
- Narrative review of choline in autism, ADHD and dyslexia.
- Population
- Developmental cohorts in the reviewed literature.
- Result
- Considers choline status and neurodevelopmental conditions. It does not isolate BHMT or measure cognitive clarity as a remethylation outcome.
- Effect / Magnitude
- No BHMT or clarity effect size for this reaction is reported.
- Evidence Summary
- Neurodevelopment review, not a test of this PM against cognitive clarity.
- Limitations
- Narrative review with several choline roles outside BHMT.
- Evidence Source
- Inherited repository evidence
- Reference
- [8]
Evidence Dependency:
- Olthof et al. (2003) is also primary evidence in PM2-IC1. Derbyshire and Maes (2023) is also primary evidence in PM2-F3. Neither reuse is a second study.
Informs: Cognitive Clarity
8. References
- [1] Evans et al. (2002) — Human BHMT structure and catalytic zinc
- [2] Breksa and Garrow (1999) — BHMT zinc ligands and reaction products
- [3] Obeid (2013) — BHMT pathway and methyl-donor deficiency
- [4] Salvi and Gadda (2013) — Choline dehydrogenase and betaine formation
- [5] Olthof et al. (2003) — Low-dose betaine and plasma homocysteine
- [6] da Costa et al. (2005) — Choline depletion and post-load homocysteine
- [7] Huang et al. (2015) — Vitamin B12, fish oil and plasma homocysteine
- [8] Derbyshire and Maes (2023) — Choline in neurodevelopmental disorders
- [9] Millichap and Yee (2012) — Diet and attention-deficit/hyperactivity disorder
- [10] Liu et al. (2012) — Folate, betaine and choline interaction in rats
- [11] Park and Garrow (1999) — Methionine restriction and hepatic BHMT expression
- [12] Setoue et al. (2008) — Choline deprivation, hepatic betaine and homocysteine
- [13] Strakova et al. (2011) — Specific BHMT inhibition and methylation capacity
No validated structured conversion route is currently projected for this PM. This does not remove or reclassify its existing dietary inputs.
Mapping state: admitted-food-targets-resolved.